Generating Insights from RWD: Opportunities for Small and Mid-sized Biopharma

Optum possesses a robust range of real-world data (RWD) assets that afford small and mid-sized biopharma the unique opportunity to generate real-world evidence (RWE) across a diverse array of therapeutic areas. In a highly insightful article, Michael Sanky of Optum Life Sciences discusses data, how smaller biopharma organizations can leverage RWE, and how RWD analysis capabilities can be greatly enhanced through technologies like natural language processing. Read more here.